Healthcare Industry News: Chlamydia
News Release - February 11, 2015
Xagenic Hires Vice President of Product Development to Expand Molecular Diagnostic Offerings and Speed Pipeline-to-MarketAbbott Point of Care veteran Dr. Tom Waddell joins Xagenic
TORONTO--(Healthcare Sales & Marketing Network)--Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform poised to inform real time treatment decisions at the point of care, today announced that Tom Waddell, Ph.D., MBA has joined the Company as a Vice President leading its product development team.
“Tom’s background, technical expertise and industry knowledge make him a triple threat for Xagenic: he understands the science behind assay and platform development; he is effective in meeting the FDA and other regulatory requirements to shepherd a diagnostic offering to market; and he understands the business of producing a commercially-successful point-of-care diagnostic platform and accompanying assays,” said Timothy I. Still, CEO of Xagenic. “His unique expertise will be instrumental in cultivating and advancing Xagenic’s pipeline of rapid response, near-patient assays using our proprietary AuRA detection technology from development to commercialization.”
Waddell brings a decade of diagnostic research and development experience to Xagenic from Pro-Lab Diagnostics and most recently in the Assay Research Group of Abbott Point of Care. At Abbott, Waddell managed a team of scientists and engineers developing new product prototypes and honing the manufacturing processes associated with the production of these new tests. Waddell also worked in the group that overcame regulatory challenges with diagnostic approval, communicating with the FDA throughout the approval process for Abbott’s point-of-care (POC) diagnostic assays.
In addition to leading cross-functional teams to developing new POC diagnostics at Abbott, Waddell has a proven record of shepherding diagnostic tools from design to approval at Pro-Lab. There, Waddell developed a number of FDA Class 1 and CE-marked immunodiagnostics, including a highly profitable immunoassay for the detection of methicillin-resistant Staphylococcus aureus (MRSA).
“The Xagenic team is already making great strides in the development of the Xagenic X1™ platform,” Waddell said. “I look forward to applying my expertise to platform development as well as the design and development of a series of diagnostic assays, beginning with the Chlamydia and gonorrhea test currently in development and expanding into other pathogens in additional indications that could benefit from Xagenic’s unique amplification-based detection technology.”
Waddell has published 19 academic papers and patents and holds a Master of Science in Clinical Biochemistry and a doctorate in microbiology and immunology from the University of Guelph in Guelph, Ontario. He also holds a Master in Business Administration focused on science and technology from Queen’s University in Kingston, Ontario.
Xagenic is a privately-held molecular diagnostics company developing the Xagenic X1™ platform, a revolutionary diagnostic system designed from its inception for use in a clinician’s office. The Xagenic X1 platform will allow users to perform lab-quality molecular diagnostic tests in the physician office. With a time-to-result of 20 minutes, the system is poised to transform the way healthcare is delivered. The Company is backed by Domain Associates, CTI Life Sciences Fund, the Ontario Capital Growth Corporation, BDC Capital and Qiagen. Xagenic was the 2014 Frost & Sullivan Point-of-Care Diagnostics New Product Innovation Leadership Award winner. The Company is headquartered in Toronto with a San Francisco office. For more information, please visit www.xagenic.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.